WEREWOLF THERAPEUTICS, INC. Variable Lease, Cost
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Variable Lease, Cost of $1.07 million for the 12-month period ending 2025-12-31, per its S-4 filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. variable lease, cost for the quarter ending 2022-12-31 was $293.00K, a 193.00% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. variable lease, cost for the quarter ending 2022-09-30 was $263.00K, a 165.66% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. variable lease, cost for the quarter ending 2022-06-30 was $183.00K, a 84.85% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. variable lease, cost for the quarter ending 2021-12-31 was $100.00K.
- WEREWOLF THERAPEUTICS, INC. variable lease, cost for fiscal 2023 was $1.21M, a 44.56% increase from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. variable lease, cost for fiscal 2022 was $837.00K, a 110.30% increase from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. variable lease, cost for fiscal 2021 was $398.00K, a 91.35% increase from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. variable lease, cost for fiscal 2020 was $208.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.07M S-4 · filed 2026-09-22 | |||
| 2024-12-31 | $1.28M S-4 · filed 2026-09-22 | |||
| 2023-12-31 | $1.21M 10-K · filed 2025-03-11 | |||
| 2022-12-31 | $293.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $556.00K derived: sum of 2 quarters · filed 2024-03-07 | $739.00K derived: sum of 3 quarters · filed 2024-03-07 | $837.00K 10-K · filed 2024-03-07 |
| 2022-09-30 | $263.00K 10-Q · filed 2022-11-10 | $446.00K derived: sum of 2 quarters · filed 2022-11-10 | $544.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $183.00K 10-Q · filed 2022-08-11 | $281.00K 10-Q · filed 2022-08-11 | ||
| 2021-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $199.00K derived: sum of 2 quarters · filed 2023-03-23 | $298.00K derived: sum of 3 quarters · filed 2023-03-23 | $398.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $99.00K 10-Q · filed 2022-11-10 | $198.00K derived: sum of 2 quarters · filed 2022-11-10 | $298.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $99.00K 10-Q · filed 2022-08-11 | $199.00K 10-Q · filed 2022-08-11 | ||
| 2020-12-31 | $208.00K 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |